Verónica Romero-Ferreiro, Lorena García-Fernández, José Miguel Biscaia, Carmen Romero Ferreiro, Rocío González-Soltero, Mónica De la Fuente, Miguel A Álvarez-Mon, Rolf Wynn, Roberto Rodriguez-Jimenez
{"title":"益生菌对精神分裂症患者c -反应蛋白水平的影响:来自系统回顾和荟萃分析的证据。","authors":"Verónica Romero-Ferreiro, Lorena García-Fernández, José Miguel Biscaia, Carmen Romero Ferreiro, Rocío González-Soltero, Mónica De la Fuente, Miguel A Álvarez-Mon, Rolf Wynn, Roberto Rodriguez-Jimenez","doi":"10.1016/j.ctim.2025.103126","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Inflammatory markers play a pivotal role in schizophrenia, as they provide insight into the neuroinflammatory processes occurring in the context of the disorder. Elevated levels of these markers, particularly C-reactive protein (CRP), can indicate an underlying immune system dysregulation, potentially influencing symptom severity and progression. Recognizing these markers has led to investigate the use of probiotics as an adjuvant to improve the treatment of schizophrenia. The main objective of this study is to rigorously evaluate the efficacy of probiotics in reducing plasma levels of CRP in patients with schizophrenia.</p><p><strong>Methods: </strong>A systematic search and meta-analysis were conducted to review randomized clinical trials following the PRISMA methodology. The following search strategy ((SCHIZO* OR PSYCHOTIC OR PSYCHOSES) AND (PROBIOTIC* OR BIFIDOBACTER* OR LACTOBACILL*)) was used for searching publications between June-December 2024 on the PubMed, Web of Science, and APA PsycINFO databases. Individual study quality was assessed with the Cochrane risk of bias (RoB2) and the certainty of total evidence was assessed with the GRADE system.</p><p><strong>Results: </strong>The primary outcome assessed was the impact of probiotic supplementation on plasma CRP levels. Out of 78 studies initially identified, 4 were finally included in the meta-analysis. Three out four studies found a significant reduction in high-sensitivity C-reactive protein levels in the supplemented compared with the placebo group. The pooled analysis revealed a significant reduction in CRP levels with probiotic supplementation, with a standardized mean difference (SMD) of -0.46, (95% CI -0.719; -0.201; p = 0.001).</p><p><strong>Conclusions: </strong>The synthesis and meta-analysis of available literature provide evidence for the potential role of probiotics in the reduction of serum CRP in schizophrenia compared with placebo. However, more clinical trials with better control of experimental design are needed before a clear recommendation as adjuvant therapy can be made.</p>","PeriodicalId":10545,"journal":{"name":"Complementary therapies in medicine","volume":" ","pages":"103126"},"PeriodicalIF":3.3000,"publicationDate":"2025-01-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Effect of Probiotics on C-Reactive Protein Levels in Schizophrenia: Evidence from a Systematic Review and Meta-Analysis.\",\"authors\":\"Verónica Romero-Ferreiro, Lorena García-Fernández, José Miguel Biscaia, Carmen Romero Ferreiro, Rocío González-Soltero, Mónica De la Fuente, Miguel A Álvarez-Mon, Rolf Wynn, Roberto Rodriguez-Jimenez\",\"doi\":\"10.1016/j.ctim.2025.103126\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>Inflammatory markers play a pivotal role in schizophrenia, as they provide insight into the neuroinflammatory processes occurring in the context of the disorder. Elevated levels of these markers, particularly C-reactive protein (CRP), can indicate an underlying immune system dysregulation, potentially influencing symptom severity and progression. Recognizing these markers has led to investigate the use of probiotics as an adjuvant to improve the treatment of schizophrenia. The main objective of this study is to rigorously evaluate the efficacy of probiotics in reducing plasma levels of CRP in patients with schizophrenia.</p><p><strong>Methods: </strong>A systematic search and meta-analysis were conducted to review randomized clinical trials following the PRISMA methodology. The following search strategy ((SCHIZO* OR PSYCHOTIC OR PSYCHOSES) AND (PROBIOTIC* OR BIFIDOBACTER* OR LACTOBACILL*)) was used for searching publications between June-December 2024 on the PubMed, Web of Science, and APA PsycINFO databases. Individual study quality was assessed with the Cochrane risk of bias (RoB2) and the certainty of total evidence was assessed with the GRADE system.</p><p><strong>Results: </strong>The primary outcome assessed was the impact of probiotic supplementation on plasma CRP levels. Out of 78 studies initially identified, 4 were finally included in the meta-analysis. Three out four studies found a significant reduction in high-sensitivity C-reactive protein levels in the supplemented compared with the placebo group. The pooled analysis revealed a significant reduction in CRP levels with probiotic supplementation, with a standardized mean difference (SMD) of -0.46, (95% CI -0.719; -0.201; p = 0.001).</p><p><strong>Conclusions: </strong>The synthesis and meta-analysis of available literature provide evidence for the potential role of probiotics in the reduction of serum CRP in schizophrenia compared with placebo. However, more clinical trials with better control of experimental design are needed before a clear recommendation as adjuvant therapy can be made.</p>\",\"PeriodicalId\":10545,\"journal\":{\"name\":\"Complementary therapies in medicine\",\"volume\":\" \",\"pages\":\"103126\"},\"PeriodicalIF\":3.3000,\"publicationDate\":\"2025-01-09\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Complementary therapies in medicine\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1016/j.ctim.2025.103126\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"INTEGRATIVE & COMPLEMENTARY MEDICINE\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Complementary therapies in medicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/j.ctim.2025.103126","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"INTEGRATIVE & COMPLEMENTARY MEDICINE","Score":null,"Total":0}
引用次数: 0
摘要
背景:炎症标志物在精神分裂症中起着关键作用,因为它们提供了对精神分裂症背景下发生的神经炎症过程的洞察。这些标志物,特别是c反应蛋白(CRP)水平升高,可能表明潜在的免疫系统失调,可能影响症状的严重程度和进展。认识到这些标记导致研究使用益生菌作为辅助剂来改善精神分裂症的治疗。本研究的主要目的是严格评估益生菌在降低精神分裂症患者血浆CRP水平方面的疗效。方法:对采用PRISMA方法的随机临床试验进行系统检索和荟萃分析。以下搜索策略((SCHIZO* OR psychiatric OR PSYCHOSES)和(PROBIOTIC* OR BIFIDOBACTER* OR LACTOBACILL*))用于检索PubMed、Web of Science和APA PsycINFO数据库中2024年6月至12月之间的出版物。采用Cochrane偏倚风险(RoB2)评估个体研究质量,采用GRADE系统评估总证据的确定性。结果:评估的主要结果是益生菌补充对血浆CRP水平的影响。在最初确定的78项研究中,有4项最终纳入了荟萃分析。四分之三的研究发现,与安慰剂组相比,补充剂组的高敏c反应蛋白水平显著降低。合并分析显示,补充益生菌后CRP水平显著降低,标准化平均差异(SMD)为-0.46,(95% CI -0.719;-0.201;P = 0.001)。结论:对现有文献的综合和荟萃分析为益生菌与安慰剂相比在降低精神分裂症患者血清CRP方面的潜在作用提供了证据。然而,需要更多的临床试验和更好的实验设计控制,才能明确推荐作为辅助治疗。
Effect of Probiotics on C-Reactive Protein Levels in Schizophrenia: Evidence from a Systematic Review and Meta-Analysis.
Background: Inflammatory markers play a pivotal role in schizophrenia, as they provide insight into the neuroinflammatory processes occurring in the context of the disorder. Elevated levels of these markers, particularly C-reactive protein (CRP), can indicate an underlying immune system dysregulation, potentially influencing symptom severity and progression. Recognizing these markers has led to investigate the use of probiotics as an adjuvant to improve the treatment of schizophrenia. The main objective of this study is to rigorously evaluate the efficacy of probiotics in reducing plasma levels of CRP in patients with schizophrenia.
Methods: A systematic search and meta-analysis were conducted to review randomized clinical trials following the PRISMA methodology. The following search strategy ((SCHIZO* OR PSYCHOTIC OR PSYCHOSES) AND (PROBIOTIC* OR BIFIDOBACTER* OR LACTOBACILL*)) was used for searching publications between June-December 2024 on the PubMed, Web of Science, and APA PsycINFO databases. Individual study quality was assessed with the Cochrane risk of bias (RoB2) and the certainty of total evidence was assessed with the GRADE system.
Results: The primary outcome assessed was the impact of probiotic supplementation on plasma CRP levels. Out of 78 studies initially identified, 4 were finally included in the meta-analysis. Three out four studies found a significant reduction in high-sensitivity C-reactive protein levels in the supplemented compared with the placebo group. The pooled analysis revealed a significant reduction in CRP levels with probiotic supplementation, with a standardized mean difference (SMD) of -0.46, (95% CI -0.719; -0.201; p = 0.001).
Conclusions: The synthesis and meta-analysis of available literature provide evidence for the potential role of probiotics in the reduction of serum CRP in schizophrenia compared with placebo. However, more clinical trials with better control of experimental design are needed before a clear recommendation as adjuvant therapy can be made.
期刊介绍:
Complementary Therapies in Medicine is an international, peer-reviewed journal that has considerable appeal to anyone who seeks objective and critical information on complementary therapies or who wishes to deepen their understanding of these approaches. It will be of particular interest to healthcare practitioners including family practitioners, complementary therapists, nurses, and physiotherapists; to academics including social scientists and CAM researchers; to healthcare managers; and to patients. Complementary Therapies in Medicine aims to publish valid, relevant and rigorous research and serious discussion articles with the main purpose of improving healthcare.